doi:10.1186/s12937-016-0207-4
Many providers evaluate patient health history, weight goals, and lifestyle habits before recommending a treatment path
In the latest JAMA Medical News podcast, Jennifer Abbasi interviews Rita Kalyani, MD, about investigational therapies including retatrutide, a triple agonist showing high efficacy for glycemic control and weight loss, and new oral options like orforglipron
Wish you the best
Rare but serious side effects include hypoglycemia, acute pancreatitis, gallbladder or biliary disease, kidney complications, retinopathy, and low platelet count
Similarly, the sample size in the TRIUMPH1 knee OA basket is designed to provide at least 90% power to detect a clinically meaningful benefit of retatrutide 9 and 12 mg versus placebo in the change in WOMAC pain subscale score, assuming each dose is analysed separately in parallel using a Satterthwaite t test at a 2sided significance level of 0.0125, accounting for differences that have been observed historically in variability between placebo and active arms